Ultrasound-guided radiofrequency ablation for the treatment of hepatic metastases:analysis of 136 cases
ZHANG Hui,YANG Wei,GAO Wen,YAN Kun,WU Jin-yu,YIN Shan-shan,WANG Yan-bin,CHEN Min-hua
DOI: https://doi.org/10.3969/j.issn.1672-6448.2005.06.015
2005-01-01
Abstract:Objective To investigate the therapeutic effects of ultrasound-guided radiofrequency ab- lation(RFA)in the treatment of hepatic metastases and to assess its clinical significance.Methods A total of 136 patients with 347 hepatic metastases underwent RFA treatment(tumor size,1.1-7.7cm in grea- test dimension).Of these,99 patients had hepatic metastases from digestive tract carcinomas,17 from the breast,12 from the lung and 8 from other primary carcinomas.Before initial RFA procedure,57 patients had single lesion,42 had more than 3 lesions.The tumors more than 3.5 cm were treated with multiple overlap- ping ablations.All the patients underwent echanced CT scan 1 month after RFA.Follow-up ranged from 3 to 51 months.Results The tumor necrosis rate and local residue rate were 95.1% and 4.9%,respectively, according to enhanced CT examination 24 h or 1 month after RFA.Local recurrence or enlargement occurred in 39 tumors(11.2%)2～19 months after treatment.The local tumor necrosis rate and recurrence rate after RFA were closely associated with the size of the focuses.New metastases in other sites of the liver were found in 55 patients(40.4%)1～16 months after RFA.The less the focuses at initial RFA,the less the new metasteses of the liver.The mean survival time was(26.22±1.85)months.The 1-,2-and 3-year survival rates were 80.3%,43.8% and 28.8%,respectively.Three cases developed severe complications,and all recovered by conservative therapy.Conclusions Ultrasound-guided RFA is an effective treatment option for hepatic metastases with high local necrosis and low complication rates.It can prolong survival time, especially for patient with single lesion.In addition,it can be repeatedly used for intrahepatic recurrence and metastases and therefore has good prospect in treating hepatic metastases.